Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 3/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 13/20 | 0.35 |
| ▸ | KDM6B | O15054 | 5/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5477176 | 0.91 | KDM4C (0.41) | HSD17B2KDM4CADRA2A | |
| SCHEMBL5484793 | 0.88 | HSD17B2 (0.40) | HSD17B2KDM4CKDM6BHSD17B1 | |
| SCHEMBL5472249 | 0.85 | HTR1A (0.45) | KDM4CKDM6B | |
| SCHEMBL5175490 | 0.83 | KCNH2 (0.33) | KDM4C | |
| SCHEMBL5471017 | 0.80 | KDM4C (0.33) | KDM4CADRA2A | |
| SCHEMBL5173373 | 0.79 | KDM4C (0.43) | HSD17B2KDM4CKDM6BADRA2A | |
| SCHEMBL5471598 | 0.79 | HTR1A (0.45) | — | |
| SCHEMBL13243645 | 0.74 | KDM4C (0.37) | HSD17B2KDM4CKDM6BMAP3K14ADRA2A | |
| SCHEMBL5474827 | 0.74 | HSD17B2 (0.41) | HSD17B2KDM4CKDM6BMAP3K14HSD17B1 | |
| SCHEMBL5475424 | 0.74 | HTR1A (0.48) | KDM4CKDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | SCHERING AG (DE) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | TNF, CXCL8, MPO | HSD17B2 1154/4885KDM4C 3261/4885KDM6B 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.